SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-010273
Filing Date
2023-01-18
Accepted
2023-01-18 17:12:02
Documents
17
Period of Report
2023-01-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d451832d8k.htm   iXBRL 8-K 29618
2 EX-1.1 d451832dex11.htm EX-1.1 178427
3 EX-5.1 d451832dex51.htm EX-5.1 7139
4 EX-99.1 d451832dex991.htm EX-99.1 8208
8 GRAPHIC g451832g0118095454317.jpg GRAPHIC 2744
9 GRAPHIC g451832g0118103831800.jpg GRAPHIC 2838
  Complete submission text file 0001193125-23-010273.txt   410511

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fulc-20230117.xsd EX-101.SCH 2856
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20230117_lab.xml EX-101.LAB 17978
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20230117_pre.xml EX-101.PRE 11262
11 EXTRACTED XBRL INSTANCE DOCUMENT d451832d8k_htm.xml XML 3350
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 23535109
SIC: 2834 Pharmaceutical Preparations